N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=85 Assessing Toxicity of Waterpipe Tobacco Smoking
Waterpipe Smoking
Primary: Comparing Cotinine Pre-to-post Change Between 2 Waterpipe Smoking Sessions: Heating Waterpipe Tobacco by (a) Charcoal vs (b) an Electric Head — 34.9; 26.4 ng/mL — p=0.115
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
N/A N=1,132 Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes
Tobacco Use, Cigarette Use
Primary: Very Low Nicotine Content (VLNC) Misperception — 3.12; 3.04; 3.04; 3.36 score on a scale
N/A N=150 Methods Project 4: Clinical Trial
Smoker
Primary: Smoke-free Days — 14.5; 0; 0 days
N/A N=359 Novel Determinants and Measures of Smokeless Tobacco Use: Study 1
Smokeless Tobacco Use · Tobacco Dependence
Primary: Extent of Toxicity: Mean of Median Values of NNK+NNN in 7 Smokeless Tobacco Brands — 2.4; 2.25; 3.19; 5.51 ug/g
Phase 2 N=67 Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function
Endothelial Dysfunction
Primary: Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0 — 4.08; 2.77; 2.97; 2.66 % of preocclusion diameter
N/A N=231 A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.
Tobacco Use
Primary: Summary of Urine Total NNAL Amount Excreted and Absolute Change From Baseline (ng/24 Hour) by Study Group and Study Day (mITT Population) — 511.889; 581.676; 548.751…
N/A N=10 IQOS (Non-Cigarette Tobacco Product) Pilot Study
Smoking · Tobacco Use
Primary: Number of Participants Who Prefer IQOS — 7 Participants
Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
N/A N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
N/A N=1,257 Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
Tobacco Product Beliefs and Use
Primary: General Relative Harm Perception — 3.04; 2.76; 2.84; 3.19 score on a scale
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 4 N=58 Tobacco and Socioeconomic Disadvantage
Tobacco Smoking
Primary: Self-reported Serious Quit Attempt Measured Via the 'Quitting Preparation and Actions Questionnaire' — 5; 10; 6 Participants — p=<0.05
N/A N=64 Cigarette and E-cigarette Nicotine Content in an Electronic Tobacco Marketplace (ETM)
Tobacco Use
Primary: Number of Cigarettes Purchased — 154.7; 119.2 average number of cigarettes
N/A N=40 Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure
Smoking Behaviors
Primary: Number of Puffs Taken (Video-scored Smoking Behavior Outcome 1) — 15.8; 16.7; 19.1; 19.6 puffs
N/A N=30 Sugars in Cigarettes
Tobacco Use
Primary: Impact of Cigarette Sugar Content on Product Satisfaction. — 4.09; 3.89; 3.92; 4.39 units on a scale
N/A N=832 Testing an Organizational Change Model to Address Smoking in Mental Healthcare
Nicotine Dependence
Primary: Client Reported Tobacco Medications — 48; 28; 62; 24 Participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 2 N=391 Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine
Tobacco Use Disorder
Primary: Product Effect on Complete Substitution for Smoking — 56; 56 participants